All In Biotech

Drug Trial Radar · NCT07684599

A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 610 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

610

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Jul 23, 2029

Study completion Sep 18, 2031

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
ENGOT, GOG, APGOT
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.

Conditions

  • Neoplasms, Endometrial

Interventions

  • Mocertatug rezetecanDrug

    Mocertatug rezetecan will be administered

  • DostarlimabDrug

    Dostarlimab will be administered

  • PembrolizumabDrug

    Pembrolizumab will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) by BICR assessmentTime frame: Up to approximately 143 weeks

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Fukuoka, Japan · Recruiting

  • GSK Investigational Site

    Fukushima, Japan · Recruiting

  • GSK Investigational Site

    Hokkaido, Japan · Recruiting

  • GSK Investigational Site

    Ibaraki, Japan · Recruiting

  • GSK Investigational Site

    Miyagi, Japan · Recruiting

  • GSK Investigational Site

    Numakunai, Japan · Recruiting

  • GSK Investigational Site

    Osaka, Japan · Recruiting

  • GSK Investigational Site

    Saitama, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Daegu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.